DGIdb - CYP19A1 Gene Record

CYP19A1 1588 Druggable Genome

Alternate Names:

1588
CYTOCHROME P450 FAMILY 19 SUBFAMILY A MEMBER 1
CYP19A1
ARO
ARO1
CPV1
CYAR
CYP19
CYPXIX
P-450AROM
107910
2594
ENSG00000137869
OTTHUMG00000131747
Cytochrome P450 19A1
Aromatase
Estrogen synthase
Cytochrome P-450AROM
P11511
CP19A_HUMAN
PA27091
CYTOCHROME P450 19A1 (AROMATASE) (EC 1.14.14.1) (CYPXIX) (ESTROGEN SYNTHETASE) (P-450AROM). [SOURCE:UNIPROT/SWISSPROT;ACC:P11511]
T13260

Gene Info:

Target Class	Enzymes
Target Subclass	EC:1.14.14
Human Readable Name	CYTOCHROME P450
Interpro Acc	IPR001128
Human Readable Name	DRUGGABLE GENOME
Interpro Name	Cytochrome P450
Uniprot Status	Swiss-Prot
Uniprot Evidence	1: Evidence at protein level
Interpro Short Name	Cyt_P450
Interpro Type	Family
Target Main Class	Enzymes
Transmembrane Helix Count	2
Target Subclass	1.14.14
Gene Biotype	PROTEIN_CODING

(9 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
CYTOCHROME P450
ENZYME

Publications:

Oesterreich S et al., 2015, Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover., Breast Cancer Res Treat
Fontein DB et al., 2014, Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial., Breast Cancer Res Treat
Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res
Abrial et al., 2009, Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials., Int J Gen Med
Nabholtz, 2008, Long-term safety of aromatase inhibitors in the treatment of breast cancer., Ther Clin Risk Manag
Barnadas et al., 2009, Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial., Br. J. Cancer
Untch et al., 2008, Exemestane in early breast cancer: a review., Ther Clin Risk Manag
Koutras et al., 2009, Antiproliferative effect of exemestane in lung cancer cells., Mol. Cancer
Brueggemeier et al., 2005, Aromatase inhibitors in the treatment of breast cancer., Endocr. Rev.
Robinson, 2009, A review of the use of exemestane in early breast cancer., Ther Clin Risk Manag
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Brueggemeier, 2006, Update on the use of aromatase inhibitors in breast cancer., Expert Opin Pharmacother
Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem
Santa-Maria CA et al., 2016, Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy., Clin Cancer Res
Long et al., 2004, Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model., J. Natl. Cancer Inst.
Murphy, 1998, Molecular Action and Clinical Relevance of Aromatase Inhibitors., Oncologist
Ebert et al., [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]., Zentralbl Gynakol
Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.
Mauras et al., 2009, Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia., J. Clin. Endocrinol. Metab.
Gangadhara et al., 2009, Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women., Ther Clin Risk Manag
Nabholtz, 2006, Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention., Oncology
Milani et al., 2009, Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women., Clin Med Ther
Santen et al., 2009, History of aromatase: saga of an important biological mediator and therapeutic target., Endocr. Rev.
Cuzick, 2005, Anastrozole., Drugs Today
Rugo, 2008, The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors., Ann. Oncol.
Jakesz et al., 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a., J. Natl. Cancer Inst.
Powlin et al., 1998, Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery., Toxicol. Sci.
O'Connor et al., 1998, An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs)., Toxicol. Sci.
Miller WR, 2003, Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer., Semin Oncol
Kelly CM et al., 2010, Anastrozole., Expert Opin Drug Saf
Buzdar AU et al., 2002, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., Cancer
Ashirmetov et al., [The role of the parasympathetic nervous system in the regulation of microsomal monooxygenase activity in the liver of rats]., Fiziol Zh
Siraki et al., 2007, Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis., Chem. Res. Toxicol.
Shirakawa et al., 2006, Aminoglutethimide prevents excitotoxic and ischemic injuries in cortical neurons., Br. J. Pharmacol.
Greco et al., HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines., J Drug Target
Martínez-Campa et al., 2005, Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells., Breast Cancer Res. Treat.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Block et al., 1992, Aminoglutethimide in malignant melanoma. A phase II study., Am. J. Clin. Oncol.
Iasinskaia, [Effect of reducing agents-antioxidants on rat uterine aromatase activity in vitro]., Ukr Biokhim Zh (1999)
Raman et al., 2002, Aromatase inhibitors for male infertility., J. Urol.
Cepa et al., 2005, Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation., J. Med. Chem.
Dunkel, 2006, Use of aromatase inhibitors to increase final height., Mol. Cell. Endocrinol.
Herzog et al., 1998, Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism., Neurology
Yamamoto et al., 1990, Inhibitory effect of a new androstenedione derivative, 14 alpha-hydroxy-4-androstene-3,6,17-trione (14 alpha-OHAT) on aromatase activity of human uterine tumors., J. Steroid Biochem.
Varela C et al., 2012, New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation., J Med Chem
Edmunds et al., The effects of dietary phytoestrogens on aromatase activity in human endometrial stromal cells., Reprod. Nutr. Dev.
Ohnishi et al., 1997, Direct inhibitions of the activities of steroidogenic cytochrome P-450 mono-oxygenase systems by anticonvulsants., J. Steroid Biochem. Mol. Biol.
Neves MA et al., 2009, An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors., Eur J Med Chem
Chan et al., 1986, Inhibition of follicle-stimulating hormone induction of aromatase activity in porcine granulosa cells by thyroxine and triiodothyronine., Endocrinology
Mendelson et al., 1984, Regulation of aromatase activity of cultured adipose stromal cells by catecholamines and adrenocorticotropin., Mol. Cell. Endocrinol.
Horie et al., 1987, Sex difference in responsiveness to Aztreonam of monooxygenase system in liver microsomes from rats., Biochem. Pharmacol.
Fiorelli et al., 1999, Estrogen synthesis in human colon cancer epithelial cells., J. Steroid Biochem. Mol. Biol.
Maffei et al., 2004, Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment., J. Clin. Endocrinol. Metab.
Brueggemeier et al., 2005, Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer., J. Steroid Biochem. Mol. Biol.
Coombes et al., 1984, 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer., Lancet
Moretti et al., 1997, Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats., J. Cardiovasc. Pharmacol.
Kao YC et al., 1998, Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study., Environ Health Perspect

TESTOLACTONE CYP19A1

Interaction Score: 5.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
11792932 16190763 16766117 9521275 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
CHEMBL572637 CYP19A1

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19500885

Sources:
DTC
CHEMBL1077603 CYP19A1

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22475216

Sources:
DTC
AMINOGLUTETHIMIDE CYP19A1

Interaction Score: 3.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD
ANASTROZOLE CYP19A1

Interaction Score: 2.94

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name anastrozole,Arimidex

PMIDs:
19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD
EXEMESTANE CYP19A1

Interaction Score: 2.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name exemestane ,Aromasin

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
26536870 24590773 20048079 20360896 18728707 19156139 19337436 19930708 15814851 19436613 11752352 17020418

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ARIMIDEX CYP19A1

Interaction Score: 1.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC
ATAMESTANE CYP19A1

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
None found

Sources:
TdgClinicalTrial
LETROZOLE CYP19A1

Interaction Score: 1.82

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name letrozole ,Femara

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
ISOPROPYL ALCOHOL CYP19A1

Interaction Score: 1.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6409434

Sources:
NCI
FORMESTANE CYP19A1

Interaction Score: 0.91

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6150277

Sources:
NCI
AZTREONAM CYP19A1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3566801

Sources:
NCI
LIAROZOLE CYP19A1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NARINGENIN CYP19A1

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
9435150

Sources:
TTD
ALENDRONIC ACID CYP19A1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14715828

Sources:
NCI
ANDROSTENEDIONE CYP19A1

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2214767

Sources:
NCI
FADROZOLE CYP19A1

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
ATROPINE CYP19A1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2128054

Sources:
NCI
CAPTOPRIL CYP19A1

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9268216

Sources:
NCI
HYDROQUINONE CYP19A1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10979580

Sources:
NCI
ISOPROTERENOL CYP19A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6205918

Sources:
NCI
LIOTHYRONINE SODIUM CYP19A1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3095107

Sources:
NCI
IBUPROFEN CYP19A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15964185

Sources:
NCI
PHENYTOIN CYP19A1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9182861

Sources:
NCI
GENISTEIN CYP19A1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16285913

Sources:
NCI
EPIRUBICIN CYP19A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAPECITABINE CYP19A1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
QUERCETIN CYP19A1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10704911

Sources:
NCI
TAMOXIFEN CYP19A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYCLOPHOSPHAMIDE CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PACLITAXEL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000137869
- Version: 101_38
Alternate Names:

CYP19A1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000137869

Version: 26-July-2011

Alternate Names:

CYTOCHROME P450 19A1 (AROMATASE) (EC 1.14.14.1) (CYPXIX) (ESTROGEN SYNTHETASE) (P-450AROM). [SOURCE:UNIPROT/SWISSPROT;ACC:P11511] Description

ENSG00000137869 Ensembl Gene Id

CYP19A1 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TEND: P11511
- Version: 01-August-2011
Alternate Names:

P11511 Uniprot Accession

1588 Entrez Gene Id

CYP19A1 Gene Symbol

Gene Info:

Target Main Class Enzymes

Transmembrane Helix Count 2

Target Subclass 1.14.14

Publications:
HopkinsGroom: P11511
- Version: 11-September-2012
Alternate Names:

1588 Entrez Gene Id

ENSG00000137869 Ensembl Gene Id

CP19A_HUMAN Uniprot Id

Gene Info:

Human Readable Name CYTOCHROME P450

Interpro Acc IPR001128

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME, CYTOCHROME P450

Publications:
TdgClinicalTrial: P11511
- Version: January-2014
Alternate Names:

CYP19A1 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.14.14

Publications:

PharmGKB: CYP19A1

Version: 18-August-2020

Alternate Names:

PA27091 PharmGKB ID

Gene Info:

Publications:

Desta Z et al., 2009, Antiestrogen pathway (aromatase inhibitor)., Pharmacogenet Genomics

Santa-Maria CA et al., 2016, Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy., Clin Cancer Res

Oesterreich S et al., 2015, Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover., Breast Cancer Res Treat

NCI: CYP19A1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.

Ashirmetov et al., [The role of the parasympathetic nervous system in the regulation of microsomal monooxygenase activity in the liver of rats]., Fiziol Zh

Brueggemeier et al., 2005, Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer., J. Steroid Biochem. Mol. Biol.

DTC: CYP19A1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Ferlin MG et al., 2013, Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors., J Med Chem

Varela C et al., 2012, New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation., J Med Chem

Neves MA et al., 2009, An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors., Eur J Med Chem

HingoraniCasas: ENSG00000137869
- Version: 31-May-2017
Alternate Names:

ENSG00000137869 Gene Symbol

CYP19A1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: AROMATASE
- Version: 12-May-2016
Alternate Names:

AROMATASE Gene Symbol

Gene Info:

Publications:
ChemblInteractions: ARO1
- Version: chembl_23
Alternate Names:

CYAR GENE_SYMBOL

CYP19 GENE_SYMBOL

CYP19A1 GENE_SYMBOL

Gene Info:

Publications:
TTD: Aromatase
- Version: 2020.06.01
Alternate Names:

CYP19A1 TTD Gene Abbreviation

T13260 TTD Target ID

Gene Info:

Publications:
Pharos: CYP19A1
- Version: 01-February-2022
Alternate Names:

Aromatase Gene Name

P11511 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Cytochrome P450 19A1 inhibitor

Mechanism of Interaction	Cytochrome P450 19A1 inhibitor
Direct Interaction	yes
Trial Name	-

Trial Name	exemestane ,Aromasin
Novel drug target	Established target
Mechanism of Interaction	Cytochrome P450 19A1 inhibitor

Trial Name	letrozole ,Femara
Novel drug target	Established target
Mechanism of Interaction	Cytochrome P450 19A1 inhibitor

CYTOCHROME P450 19A1 (AROMATASE) (EC 1.14.14.1) (CYPXIX) (ESTROGEN SYNTHETASE) (P-450AROM). [SOURCE:UNIPROT/SWISSPROT;ACC:P11511]	Description
ENSG00000137869	Ensembl Gene Id
CYP19A1	Display Id

1588	Entrez Gene Id
ENSG00000137869	Ensembl Gene Id
CP19A_HUMAN	Uniprot Id

antagonist (inhibitory)
inhibitor (inhibitory)

CYP19A1 Gene Record

CYP19A1 1588 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs: 11792932 16190763 16766117 9521275 11752352

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19500885

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22475216

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cytochrome P450 19A1 inhibitor Direct Interaction yes Trial Name -

PMIDs: 17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources: TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Cytochrome P450 19A1 inhibitor Direct Interaction yes Trial Name anastrozole,Arimidex

PMIDs: 19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources: TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name exemestane ,Aromasin Novel drug target Established target Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs: 26536870 24590773 20048079 20360896 18728707 19156139 19337436 19930708 15814851 19436613 11752352 17020418

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name atamestane-plus-toremifene

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name letrozole ,Femara Novel drug target Established target Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs: 24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources: DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6409434

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6150277

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3566801

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 9435150

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14715828

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2214767

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2128054

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
11792932 16190763 16766117 9521275 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
19500885

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22475216

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name -

PMIDs:
17602675 16474421 16332571 11752352 16244789 17016423 17139284 1590282

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

Direct Interaction yes

Trial Name anastrozole,Arimidex

PMIDs:
19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296

Sources:
TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name exemestane ,Aromasin

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
26536870 24590773 20048079 20360896 18728707 19156139 19337436 19930708 15814851 19436613 11752352 17020418

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name atamestane-plus-toremifene

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name letrozole ,Femara

Novel drug target Established target

Mechanism of Interaction Cytochrome P450 19A1 inhibitor

PMIDs:
24025069 26536870 26463708 20048079 15026471 10388095 11752352 14505258

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
6409434

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6150277

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3566801

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
9435150

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
14715828

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2214767

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
2128054

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9268216

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10979580

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6205918

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3095107

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15964185

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9182861

Sources:
NCI

Interaction Types & Directionality:

n/a